Aether Industries Q1FY27 profit rises 33.6% on CEM surge
Aether Industries posted a consolidated net profit of ₹627.49 million for Q1FY27, up 33.6% YoY, supported by a 27.2% increase in revenue to ₹3,265.57 million. The growth was primarily driven by robust demand in CEM and LSM segments, with CEM contributing 51.5% of revenue. The Board also approved director re-appointments and auditor appointments for FY2027.
*this image is generated using AI for illustrative purposes only.
Aether Industries reported a consolidated net profit of ₹627.49 million for the first quarter ended June 30, 2026 (Q1FY27), marking a 33.6% year-on-year increase from ₹470.21 million in the corresponding period of the previous year. The specialty chemicals manufacturer saw its revenue from operations grow by 27.2% to ₹3,265.57 million, driven by robust demand in Contract Exclusive Manufacturing (CEM) and Large Scale Manufacturing (LSM). This growth trajectory underscores the company’s successful shift towards higher-margin business models, which has supported stable EBITDA margins despite volume fluctuations in specific segments.
The Board of Directors approved the unaudited standalone and consolidated financial results during a meeting held on July 31, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were subjected to a limited review by the statutory auditors, Suresh I Surana & Associates, who issued an unmodified conclusion.
Financial Performance Overview
The company's top-line expansion was primarily fueled by higher revenue from operations, which increased from ₹2,566.29 million in Q1FY26 to ₹3,265.57 million in Q1FY27. Total income rose to ₹3,342.46 million from ₹2,587.09 million year-ago. Other income also contributed significantly, jumping to ₹76.89 million from ₹20.80 million in the prior year's first quarter.
Profit before tax stood at ₹834.53 million, up from ₹616.26 million previously. After accounting for total tax expenses of ₹207.04 million, the net profit attributable to owners reached ₹627.49 million. Earnings per share (basic) were reported at ₹4.77, an increase from ₹3.55 in Q1FY26.
The following table summarises the key consolidated financial metrics for the quarter:
| Metric: | Q1FY27 (Unaudited) | Q1FY26 (Unaudited) | Change (%) |
|---|---|---|---|
| Revenue from Operations: | ₹3,265.57 million | ₹2,566.29 million | +27.2% |
| Total Income: | ₹3,342.46 million | ₹2,587.09 million | +29.2% |
| EBITDA: | ₹1,028 million* | ₹785 million* | +31% |
| Profit Before Tax: | ₹834.53 million | ₹616.26 million | +35.4% |
| Net Profit: | ₹627.49 million | ₹470.21 million | +33.6% |
| EPS (Basic): | ₹4.77 | ₹3.55 | +34.4% |
Note: EBITDA figures are derived from management commentary; exact EBITDA line item not explicitly separated in the provided P&L table but referenced in existing analysis.
Segment Mix and Revenue Drivers
Revenue by business model in Q1FY27 was dominated by Contract Exclusive Manufacturing (CEM), which contributed 51.5% (₹1,656 million), followed by Large Scale Manufacturing (LSM) at 39.1% (₹1,258 million), and Contract Research & Manufacturing Services (CRAMS) at 9.3% (₹301 million). Regionally, domestic sales accounted for 62.5% of revenue, while exports, including deemed exports and SEZ sales, made up 37.5%.
By end-use sector, Pharma remained the largest contributor at 32.2%, followed by Oil & Gas at 31.4%. Material Science contributed 16.6%, while Agro accounted for 9.5%. The company noted that Oil & Gas and Material Science are expected to be main drivers despite new product launches in Pharmaceuticals and Agrochemicals.
Operational Milestones and Corporate Actions
Aether Industries spent ₹198.07 million on Research & Development in Q1FY27, accounting for 6.16% of revenues. Key operational highlights include:
- Site 5 Phase One: Two production blocks commenced commercial operation in Q1FY27, with revenue contribution expected from Q2FY27 onwards.
- Site 3++: Commercial production started with ramp-up ongoing.
- Customer Acquisition: 10 new customers were onboarded across all business models during Q1FY27.
During the same meeting, the Board approved several strategic actions:
- Director Re-appointments: Ashwin Desai as Managing Director, and Purnima Desai, Rohan Desai, and Aman Desai as Whole-time Directors, each for a five-year term effective October 1, 2026, subject to shareholder approval.
- Auditor Appointments: CA Riddhi Chitaliya as Internal Auditor, and M/s. PAAA & Associates as Cost Auditor for FY2027.
- Senior Managerial Personnel: Designation of six employees including Denish Dodhiyawala and Parag Detroja as Senior Managerial Personnel effective August 1, 2026.
- AGM Notice: The 14th AGM is scheduled for September 11, 2026, via video conferencing.
Insurance Settlements and Material Disclosures
A material factor influencing the current quarter's results was the settlement of an insurance claim stemming from a fire at Manufacturing Facility-II in November 2023. During Q1FY27, the insurance company paid a balance settlement of ₹260.05 million, comprising ₹225.05 million for asset loss and ₹35.00 million for financial loss/profit (FLOP). The company had previously written off damaged property amounting to ₹299.68 million during the quarter ended March 31, 2026.
Additionally, the company recognized a loss of ₹70.00 million in the previous fiscal year due to a fire at an external warehouse in March 2026. An insurance claim for this incident is currently under assessment, with any recovery to be recognized upon reasonable certainty of receipt.
What the Numbers Show
The shift in business model towards higher-margin CEM and CRAMS contracts is clearly reflected in the financials. While LSM revenue declined slightly from ₹1,325 million in Q1FY26 to ₹1,258 million in Q1FY27, CEM revenue surged by 75% to ₹1,656 million. This mix shift, combined with price-led demand in LSM, has supported stable EBITDA margins at 31% despite volume fluctuations in specific segments. The significant R&D spend (6.16% of revenue) indicates continued investment in innovation, which management expects to drive future growth through new product launches and customer acquisitions.
Historical Stock Returns for Aether Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.48% | +2.33% | +15.10% | +70.27% | +116.83% | +112.18% |
How will the commencement of Site 5 Phase One and the ramp-up of Site 3++ impact Aether Industries' capacity utilization and margin profile in Q2FY27?
Given the significant insurance settlement of ₹260.05 million in Q1FY27, what is the expected trajectory for normalized net profit margins once such one-off gains are excluded?
With Oil & Gas and Material Science identified as primary growth drivers, how does Aether plan to mitigate potential regulatory or cyclical risks associated with these sectors compared to its Pharma portfolio?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
